Literature DB >> 1566240

Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration.

P Wiedemann1.   

Abstract

The goal of this review is to present the current knowledge on specific growth factor involvement in posterior segment eye disease. Growth factors can be defined as multifunctional signals which modify cell growth or proliferation, alone or in concert, by binding to specific cell surface receptors. Their biological effects on cells include cell adhesion, migration, survival, differentiation, extracellular matrix secretion, protease and protease inhibitor release, production of other growth activities, and angiogenesis. Growth factors couple the cell to the microenvironment. As some growth factors are soluble mediators of wound repair and angiogenesis, it seems possible that proliferative vitreoretinopathy and proliferative diabetic retinopathy are caused or aggravated by these factors. Other factors act as survival factors and can possibly prevent retinal degeneration. The multifunctional nature of growth factors makes it probable that practical uses will be found for these agents in the future.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1566240     DOI: 10.1016/0039-6257(92)90115-a

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  47 in total

1.  Enhancement of dedifferentiation and myoid differentiation of retinal pigment epithelial cells by platelet derived growth factor.

Authors:  A Ando; M Ueda; M Uyama; Y Masu; S Ito
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Transforming growth factor-β neutralizing antibodies inhibit subretinal fibrosis in a mouse model.

Authors:  Han Zhang; Zhe-Li Liu
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

3.  Vitrectomy for traction macular detachment in diabetic retinopathy.

Authors:  P Meier; P Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-09       Impact factor: 3.117

Review 4.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

5.  [Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model].

Authors:  J Beutel; M Lüke; K-U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

6.  Partial characterization of a putative new growth factor present in pathological human vitreous.

Authors:  C Pombo; L Bokser; X Casabiell; J Zugaza; M Capeans; M Salorio; F Casanueva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-03       Impact factor: 3.117

Review 7.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

8.  Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes.

Authors:  Murat Atabey Ozer; Nihat Polat; Serkan Ozen; Tevfik Ogurel; Hakan Parlakpinar; Nigar Vardi
Journal:  Int Ophthalmol       Date:  2016-08-05       Impact factor: 2.031

9.  Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction.

Authors:  Eri Takahashi; Osamu Nagano; Takatsugu Ishimoto; Toshifumi Yae; Yoshimi Suzuki; Takeshi Shinoda; Satoshi Nakamura; Shinichiro Niwa; Shun Ikeda; Hisashi Koga; Hidenobu Tanihara; Hideyuki Saya
Journal:  J Biol Chem       Date:  2009-12-04       Impact factor: 5.157

10.  Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

Authors:  R G Williams; S Chang; M R Comaratta; G Simoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.